3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Breast Neoplasms
127
Neoplasm Metastasis
14
Neoplasms
9
Advanced Breast Cancer
6
Endometrial Neoplasms
5
Recurrence
4
Hereditary Sensory and Autonomic Neuropathies
4
Triple Negative Breast Neoplasms
3
Prostatic Neoplasms
3
Ovarian Neoplasms
3
Neoplasms, Hormone-Dependent
3
Carcinoma, Non-Small-Cell Lung
3
Carcinoma, Lobular
3
Carcinoma, Ductal, Breast
3
Squamous Cell Carcinoma of Head and Neck
2
Polycystic Ovary Syndrome
2
Osteoporosis
2
Neoplasms by Site
2
Lymphoma, Non-Hodgkin
2
Head and Neck Neoplasms
2
HR+/HER2- Breast Cancer
2
Breast Neoplasms, Male
2
Breast Diseases
2
Bone Diseases, Metabolic
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Osteitis Deformans
1
Multiple Endocrine Neoplasia Type 1
1
Mesothelioma, Malignant
1
Interventions
Trabectedin
4
Doxorubicin
4
toripalimab
2
brigimadlin
2
belinostat
2
Fulvestrant
2
Dexamethasone
2
tanespimycin
1
soblidotin
1
siremadlin
1
selinexor
1
ridaforolimus
1
ribociclib
1
pembrolizumab
1
olaratumab
1
milademetan
1
enzalutamide
1
cemiplimab
1
atezolizumab
1
TTI-621
1
Sugars
1
Quality of Life
1
Patient Reported Outcome Measures
1
Molecular Diagnostic Techniques
1
Midazolam
1
Letrozole
1
Injections
1
Immunotherapy
1
Imatinib Mesylate
1
Ifosfamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Liposarcoma
×
Letrozole
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled